Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
01 Jun 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
SEK 288.40
19.0% undervalued intrinsic discount15 Aug
SEK 233.60
1Y
51.7%7D
0.09%